Variants of the CYP11B2 gene predict response to therapy with candesartan.
In a prospective trial, patients with an elevated diastolic blood pressure (above 95 mm Hg) received high-dose (16 mg) or low-dose (8 mg) candesartan in addition to standardised medication. A positive response to treatment was defined as a diastolic blood pressure <85 mm Hg at follow-up. Genotyping for two candidate genes was performed in 116 patients. Genotypes of the CYP11B2 promotor polymorphism significantly predicted a positive response to treatment (CC: 67%; TC: 34%; TT: 21%; p=0.005).
Ortlepp
Jan R
JR
Medical Clinic I, University Hospital of Aachen, Pauwelsstrasse 30, 52057 Aachen, Germany. jrortlepp@ukaachen.de
Hanrath
Peter
P
Mevissen
Vera
V
Kiel
Gerhard
G
Borggrefe
Martin
M
Hoffmann
Rainer
R
D000368:Aged; D000704:Analysis of Variance; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D016009:Chi-Square Distribution; D019405:Cytochrome P-450 CYP11B2 / Q000235:genetics*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011446:Prospective Studies; D013777:Tetrazoles / Q000627:therapeutic use*
D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D019405:Cytochrome P-450 CYP11B2; C081643:candesartan